Aspirin-induced asthma: Advances in pathogenesis and management

Journal of Allergy and Clinical Immunology

Volumn 104, Issue 1, 1999, Pages 5-13

  Szczeklik, Andrew ^a   Stevenson, Donald D ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b SCRIPPS CLINIC   (United States)

Author keywords

5 lipoxygenase enzymes; Aspirin desensitization; Aspirin induced asthma; Asthma; Cyclooxygenase enzymes; Leukotriene C4 synthase; Leukotrienes

Indexed keywords

ACETYLSALICYLIC ACID; ARACHIDONATE 5 LIPOXYGENASE; CELECOXIB; CILNORIL; CORTICOSTEROID; CYCLOOXYGENASE 2; DICLOFENAC; DICLOFENAC POTASSIUM; DIFLUNISAL; DOLBID; ETODOLAC; FENOPROFEN; FENOPROFEN CALCIUM; FLURBIPROFEN; IBUPROFEN; INDOMETACIN; KETOPROFEN; KETOROLAC; LEUKOTRIENE RECEPTOR BLOCKING AGENT; MECLOFENAMATE SODIUM; MECLOFENAMIC ACID; MEFENAMIC ACID; MELOXICAM; NABUMETONE; NAPROXEN; NIMESULIDE; ORUVAL; OXAPROZIN; PARACETAMOL; PEPTIDOLEUKOTRIENE; PIROXICAM; ROFECOXIB; SALSALATE; SULINDAC; TOLMETIN; UNCLASSIFIED DRUG;

ALLERGIC ASTHMA; CLINICAL TRIAL; CORTICOSTEROID THERAPY; DESENSITIZATION; DRUG CONTRAINDICATION; DRUG CROSS REACTIVITY; DRUG HYPERSENSITIVITY; HUMAN; PATHOGENESIS; PRIORITY JOURNAL; REVIEW;

EID: 0032865987     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0091-6749(99)70106-5     Document Type: Article

References (90)

1. 1. Widal MF, Abrami P, Lenmoyez J. Anaphylaxie et idiosyncrasie. Presse Med 1922;30:189-92.
2. 2. Samter M, Beers RF. Intolerance to aspirin. Clinical studies and consideration of its pathogenesis. Ann Intern Med 1968;68:975-83.
3. 3. Drazen JM, Israel E, O'Byrne PM. Treatment of asthma with drugs modifying the leukotriene pathway. N Engl J Med 1999;340:197-206.
4. 4. Nasser SMS, Lee TH. Leukotrienes in aspirin-sensitive asthma. In: Szczeklik A, Gryglewski RJ, Vane JR, editors. Eicosanoids, aspirin and asthma. New York: Marcel Dekker, Inc; 1998. p. 317-35.
5. 5. Stevenson DD, Simon RA. Sensitivity to aspirin and nonsteroidal antiinflammatory drugs. In: Middleton E, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW, editors. Allergy: principles and practice. 5th ed. St Louis: Mosby; 1998. p. 1225-34.
6. 6. Quiralte J, Blanco C, Castillo R, Delgado J, Carillo T. Intolerance to nonsteroidal antiinflammatory drugs: results of controlled drug challenges in 98 patients. J Allergy Clin Immunol 1996;98:678-85.
7. 7. Szczeklik A. Mechanism of aspirin-induced asthma. In: Szczeklik A, Gryglewski RJ, Vane JR editors. Eicosanoids, aspirin and asthma. New York: Marcel Dekker, Inc; 1998. p. 299-315.
8. 8. Szczeklik A, Sanak M. Genetics of aspirin-induced asthma. Am J Respir Crit Care Med In press.
9. 9. Picado C, Castillo JA, Montserrat JM, Augusti-Vidal A. Aspirin intolerance as a precipitating factor of life-threatening attacks of asthma requiring mechanical ventilation. Eur Respir J 1989;2:127-9.
10. 10. Marquette CH, Saulnier F, Leroy O, Wallaert B, Chopin C, Demarcq JM, et al. Long-term prognosis for near-fatal asthma. A 6-year follow-up study of 145 asthmatic patients who underwent mechanical ventilation for near-fatal attack of asthma. Am Rev Respir Dis 1992;146:76-81.
11. 11. Bochenek G, Nizankowska E, Szczeldik A. Atopy trait in hypersensitivity to nonsteroidal anti-inflammatory drugs. Allergy 1996;51:16-23.
12. 12. Bianco S, Robuschi M, Petrigni G. Aspirin-induced tolerance in aspirin-induced asthma detected by a new challenge technique. Int Res Com Syst Med Sci 1977;5:129-30.
13. 13. Milewski M, Mastalerz L, Nizankowska E, Szczeklik A. Nasal provocation test for diagnosis of aspirin-induced asthma. J Allergy Clin Immunol 1998;101:581-6.
14. 14. Schlumberger HD. Drug-induced pseudo-allergic syndrome as exemplified by acetylsalicylic acid intolerance. In: Dukor P, Kallos P, Schlumberger HD, West GB, editors. Pseudo-allergic reactions. Involvement of drugs and chemicals. Basel: Karger; 1980. p. 125-203.
15. 15. Dahlen B, Boreus LO, Anderson P, Anderson R, Zetterstrom O. Plasma acetylsalicylic acid and salicylic acid levels during aspirin provocation in aspirin-sensitive subjects. Allergy 1994;49:43-9.
16. 16. Szczeklik A. The cyclooxygenase theory of aspirin-induced asthma. Eur RespirJ 1990;3:588-93.
17. 17. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. Nature 1971;231:232-4.
18. 18. Szczeklik A, Gryglewski RJ, Czerniawska-Mysik G. Relationship of inhibition of prostaglandin biosynthesis by analgesics to asthma attacks in aspirin-sensitive patients. BMJ 1975;1:67-9.
19. 19. Szczeklik A, Gryglewski RJ, Czemiawska-Mysik G. Clinical patterns of hypersensitivity to nonsteroidal antiinflammatory drugs and their pathogenesis. J Allergy Clin Immunol 1977;60:276-84.
20. 20. Stevenson DD, Lewis RA. Proposed mechanisms of aspirin sensitivity reactions. J Allergy Clin Immunol 1987;80:788-90.
21. 21. Lee TH. Mechanism of aspirin sensitivity. Am Rev Respir Dis 1992;145:34-6.
22. 22. Demoly P, Jaffuel D, Lequeux N, Weksler B, Creminon Ch, Michel F-B, et al. Prostaglandin H synthase 1 and 2 immunoreactivities in the bronchial mucosa of asthmatics. Am J Respir Crit Care Med 1997;155:670-5.
23. 23. Sousa AR, Pfister R, Christie PE, Lane SJ, Nasser SM, Schmitz-Schumann M, et al. Enhanced expression of cyclo-oxygenase isoenzyme 2 (COX-2) in asthmatic airways and its cellular distribution in aspirin-sensitive asthma. Thorax 1997;52:940-5.
24. 24. Couburn AS, Sladek K, Soja J. Adamek L, Nizankowska E, Szczeklik A, et al. Overexpression of leukotriene C4 synthase in bronchial biopsies from patients with aspirin-intolerant asthma. J Clin Invest 1998;101:1-13.
25. 25. Bianco S, Robuschi M, Petrigni G, Scuri M, Pietroni MG, Refini RM, et al. Efficacy and tolerability of nimesulide in asthmatic patients intolerant to aspirin. Drugs 1993;46:115-20.
26. 26. Kosnik M, Music E, Matjaz F, Suskovic S. Relative safety of meloxicam in NSAID-intolerant patients. Allergy 1998;53:1231-3.
27. 27. Hawkey CJ. COX-2 inhibitors. Lancet 1999;353:307-14.
28. 28. Szczeklik A, Sladek K, Dworski R, Nizankowska E, Soja J, Sheller J, et al. Bronchial aspirin challenge causes specific eicosanoid response in aspirin sensitive asthmatics. Am J Respir Crit Care Med 1996;154:1608-14.
29. 29. Fischer AR, Rosenberg MA, Lilly CM, Callery JC, Rubin P, Cohn J, et al. Direct evidence for a role of the mast cell in the nasal response to aspirin in aspirin-sensitive asthma. J Allergy Clin Immunol 1994;94:1046-56.
30. 30. Warren MS, Sloan SJ, Westcott JY, Hamilos D, Wenzel SE. LTE4 increases in bronchoalveolar lavage fluid (BALF) of aspirin-intolerant asthmatics (AIA) after instillation of indomethacin [abstract]. J Allergy Clin Immunol 1995:95:170.
31. 31. O'Sullivan S, Dahlen B, Dahlen S-E, Kumlin M. Increased urinary excretion of the prostaglandin D2 metabolite 9α, 11β-prostaglandin F2 after aspirin challenge supports mast cell activation in aspirin-induced airway obstruction. J Allergy Clin Immunol 1996;98:421-32.
32. 32. Szczeklik A, Dworski R, Mastalerz L, Prokop A, Sheller JR, Nizankowska E, et al. Salmeterol prevents aspirin-precipitated attacks of asthma and interferes with eicosanoids metabolism. Am J Respir Crit Care Med 1998;158:1168-72.
33. 33. Szczeklik A. Aspirin-induced asthma as a viral disease. Clin Allergy 1988:18:15-20.
34. 34. Pavord ID, Tattersfield AE. Bronchoprotective role for endogenous prostaglandin E2. Lancet 1995;345:436-8.
35. 35. Kuehl FA, Dougherty WH, Ham EA. Interactions between prostaglandins and leukotrienes. Biochem Pharmacol 1984;33:1-5.
36. 36. Christman BW, Christman JW, Dworski R, Blair IA, Prakash C. Prostaglandin E2 limits arachidonic acid availability and inhibits leukotriene B4 synthesis in rat alveolar macrophages by a nonphospholipase A2 mechanism. J Immunol 1993;151:2096-104.
37. 37. An S, Goetzl EJ. Lipid mediators of hypersensitivity and inflammation. In: Middleton E, Reed CE, Ellis EF, Adkinson NF Jr, Yunginger JW, Busse WW, editors. Allergy: principles and practice. 5th ed. St Louis: Mosby; 1998. p. 168-82.
38. 38. Kahn RM, Okanlami DA, Jacoby DB, Fryer AD. Viral infection induced dependence of neuronal M2 muscarinic receptors on cyclooxygenase in guinea pig lungs. J Gin Invest 1996;98:299-307.
39. 39. Sestini P, Armetti L, Gambaro G, Pieroni MG, Refini RM, Sala A, et al. Inhaled PGE2 prevents aspirin-induced bronchoconstriction and urinary LTE4 excretion in aspirin-sensitive asthma. Am J Respir Crit Care Med 1996;153:572-5.
40. 40. Szmidt M, Wasiak W. The influence of misoprostol (synthetic analogue of prostaglandin E1) on aspirin-induced bronchoconstriction in aspirin-sensitive asthma. J Invest Allergol Clin Immunol 1996;6:121-5.
41. 41. Smith CM, Hawksworth RJ, Thien FC, Christie PE, Lee TH. Urinary leukotriene E4 in bronchial asthma. Eur Respir J 1992;5:693-9.
42. 42. Kumlin M, Dahlen B, Bjorck T, Zetterstrom O, Granstrom E, Dahlen S-E. Urinary excretion of leukotriene E4 and 11-dehydro-thromboxane B2 in response to provocations with allergen, aspirin, leukotriene D4 and histamine in asthmatics. Am Rev Respir Dis 1992;146:96-103.
43. 43. Sladek K, Szczeklik A. Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma. Eur Respir J 1993;6:391-9.
44. 44. Ortolani C, Mirone C, Fontana A, Folco GC, Miadonna A, Montalbetti N, et al. Study of mediators of anaphylaxis in nasal wash fluids after aspirin and sodium metabisulfite nasal provocation in intolerant rhinitic patients. Ann Allergy 1987;59:106-12.
45. 45. Ferreri NR, Howland WC, Stevenson DD, Spiegelberg HL. Release of leukotrienes, prostaglandins and histamine into nasal secretions of aspirin-sensitive asthmatic during reaction to aspirin. Am Rev Respir Dis 1988;137:847-54.
46. 46. Picado C, Ramis I, Rosello J, Prat J, Bulbena O, Plaza V, et al. Release of peptido-leukotrienes into nasal secretions after local instillation of aspirin in aspirin-sensitive asthmatic patients. Am Rev Respir Dis 1992;145:65-9.
47. 47. Kowalski ML, Sliwinska-Kowalska M, Igarashi Y, White MV, Wojciechowska B, Brayton P, et al. Nasal secretions in response to acetylsalicylic acid. J Allergy Clin Immunol 1993;91:580-98.
48. 48. Mewes T, Riechelmann H, Klimek L. Increased in vitro cysteinyl leukotriene release from blood leukocytes in patients with asthma, nasal polyps, and aspirin intolerance. Allergy 1996;51:506-10.
49. 49. Penrose JF, Spector J, Baldasaro M, Xu K, Arm JP, Austen KF, et al. Molecular cloning for human LTC4 synthase: organization, nucleotide sequence and chromosomal localization to 5q35. J Biol Chem 1996;271:11356-61.
50. 50. Sanak M, Simon H-U, Szczeklik A. Leukotriene C4 synthase promoter polymorphism and risk of aspirin-induced asthma. Lancet 1997;350:1599-600.
51. 51. Sanak M, Bazan-Socha S, Szczeklik A. Leukotriene C4 synthase (LTC4s) expression in blood eosinophils of patients with asthma. Eur Respir J 1998;12(suppl 28):373s.
52. 52. Szczeklik A, Sanak M, Nizankowska E, Mastalerz L, Bochenek G, Pulka G, et al. Leukotriene C4 synthase genetic polymorphism directs urinary cysteinyl-leukotriene response to aspirin-challenge in asthma. Allergy 1998;53(suppl43):61.
53. 53. Arm JP, O'Hickey SP, Spur B, Lee TH. Airway responsiveness to histamine and leukotriene E4 in subjects with aspirin-induced asthma. Am Rev Respir Dis 1989;140:148-53.
54. 54. Serhan CN. Lipoxins and novel aspirin-triggered 15-epi-lipoxins (ATL): A jungle of cell-cell interactions or a therapeutic opportunity? Prostaglandins 1997;53:107-37.
55. 55. In KH, Asano K, Beier D, Grobholz J, Finn PW, Silverman EK, et al. Naturally occurring mutation in the human 5-lipoxygenase gene promoter that modify transcription factor binding and reporter gene transcription. J Clin Invest 1997;99:1130-7.
56. 56. Nasser SMS, Pfister R, Christie PE, Sousa AR, Barker J, Schmitz-Schumann M, et al. Inflammatory cell populations in bronchial biopsies from aspirin-sensitive asthmatic subjects. Am J Respir Crit Care Med 1996;153:90-6.
57. 57. Hamilos DL, Leung DYM, Wood R, Bean DK, Song YL, Schotman E, et al. Eosinophil infiltration in nonallergic chronic hyperplastic sinusitis with nasal polyposis (CHSINP) is associated with endothelial VCAM-1 upregulation and expression of TNF-α. Am J Respir Cell Mol Biol 1996;15:443-50.
58. 58. Sousa AR, Lams BEA, Pfister R, Christie PE, Schmilz M., Lee TH. Expression of interleukin-5 and granulocyte-macrophage colony-stimulating factor in aspirin-sensitive and non-aspirinsensitive asthmatic airways. Am J Respir Crit Care Med 1997;156:1384-9.
59. 59. Holgate ST, Bodey KS, Janezic A, Frew AJ, Kaplan AP, Teran LM. Release of Rantes, MTP-1α, and MCP-1 into asthmatic airways following endobronchial allergen challenge. Am J Respir Crit Care Med 1997;156:1377-83.
60. 60. Szczeklik A, Nizankowska E, Serafin A, Dyczek A, Duplaga M, Musial J. Autoimmune phenomena in bronchial asthma with special reference to aspirin intolerance. Am J Respir Crit Care Med 1995;152:1753-6.
61. 61. Lasalle P, Delneste Y, Gosset P, Grass-Masse H, Wallaert B, Tonnel AB. T and B cell immune response to a 55-kDa endothelial cell-derived antigen in severe asthma. Eur J Immunol 1993;23:796-803.
62. 62. Szczeklik A, Musial J, Pulka G. Autoimmune vasculitis and aortic stenosis in aspirin-induced asthma (AIA). Allergy 1997;52:352-4.
63. 63. Szczeklik A, Schmitz-Schumann M, Nizankowska E, Milewski M, Roehlig F, Virchow C. Altered distribution of IgG subclasses in aspirin-induced asthma, high IgG4, low IgG1. Clin Exp Allery 1992;22:283-7.
64. 64. Dekker JW, Nizankowska E, Schmitz-Schumann M, Pile K, Bochenek G, Dyczek A, et al. Aspirin-induced asthma and HLA-DRB1 and HLA-DPB1 genotypes. Clin Exp Allergy 1997;27:574-7.
65. 65. Nizankowska E, Duplaga M, Bochenek G, Szczeklik A, on behalf of the AIANE project. Clinical course of aspirin-induced asthma: results of AIANE. In: Szczeklik A, Gryglewski RJ, Vane JR, editors. Eicosanoids, aspirin and asthma. New York: Marcel Dekker, Inc; 1998. p. 451-71.
66. 66. Nizankowska E, Soja J, Finis G, Bochenek G, Sladek K, Domagala B, et al. Treatment of steroid-dependent bronchial asthma with cyclosporin. Eur Respir J 1995;8:1091-9.
67. 67. Settipane RA, Shrank PJ, Simon RA, Mathison DA, Christensen SC, Stevenson DD. Prevalence of cross-sensitivity with acetaminophen in aspirin-sensitive asthmatics. J Allergy Clin Immunol 1995;96:480-5.
68. 68. Andri L, Senna G, Betteli C, Givanni S, Scaricabarozzi I, Mezzelani P, et al. Tolerability of nimesulide in aspirin-sensitive patients. Ann Allergy 1994;72:29-32.
69. 69. Kowalski ML. Management of aspirin-sensitive rhinosinusitis-asthma syndrome: What role for aspirin desensitization? Allergy Proc 1992;13:175-84.
70. 70. Stevenson DD, Hankammer MA, Mathison DA, Christiansen SC, Simon RA. Aspirin desensitization/treatment of aspirin-sensitive rhinosinusitic-asthmatic patients: long term outcomes. J Allergy Clin Immunol 1996;98:751-8.
71. 71. Juergens UR, Christiansen SC, Stevenson DD, Zuraw BL. Inhibition of monocyte leukotriene B4 production after aspirin desensitization. J Allergy Clin Immunol 1995;96:148-56.
72. 72. Nasser S, Patel M, Bell GS, Lee TH. The effect of aspirin desensitization on urinary leukotriene E4 concentrations in aspirin-sensitive asthma. Am J Respir Crit Care Med 1995;151:1326-30.
73. 73. Szczeklik A, Nizankowska E, Czemiawska-Mysik G, Sek S. Hydrocortisone and airflow impairment in aspirin-induced asthma. J Allergy Clin Immunol 1985;76:530.
74. 74. Feigenbaum BA, Stevenson DD, Simon RA. Hydrocortisone sodium succinate docs not cross-react with aspirin in aspirin-sensitive patients with asthma. J Allergy Clin Immunol 1995;96:545-8.
75. 75. Weber RW, Hoffman M, Raine DA, Nelson HS. Incidence of bronchoconstriction due to aspirin, azo dyes, non-azo dyes and preservatives in a population of perennial asthmatics. J Allergy Clin Immunol 1979;64:32-7.
76. 76. Stevenson DD, Simon RA, Lumry WR, Mathison DA. Adverse reactions to tartrazme. J Allergy Clin Immunol 1986;78:182-91.
77. 77. Virchow C, Szczeklik A, Bianco S, Schmitz-Schumann M, Juhl E, Robuschi M, et al. Intolerance to tartrazme in aspirin-induced asthma: result of a multicenter study. Respiration 1988;53:20-5.
78. 78. Gerber JG, Payne NA, Oelz O, Nies, AS, Oates JA. Tartrazine and the prostaglandin system. J Allergy Clin Immunol 1979;63:289-94.
79. 79. Christie PE, Smith CM, Lee TH. The potent and selective sulfidopeptide leukotriene antagonist SK&F 104353, inhibits aspirin-induced asthma. Am Rev Respir Dis 1991;144:957-8.
80. 80. Yamamoto H, Nagata M, Kuramitsu K, Tabe K, Kiuchi H, Sakamoto Y, et al. Inhibition of analgesic-induced asthma by leukotriene receptor antagonist ON)-VC 1078. Am J Respir Crit Care Med 1994;150:254-7.
81. 81. Nasser SMS, Bell GS, Foster S. Spruce KE, Macvillan R, Williams AJ, et al. Effect of the 5-lipoxygenase inhibitor ZD 2138 on aspirin-induced asthma. Thorax 1994;49:749-56.
82. 82. Israel E, Fisher AR, Rosenberg MA, Lilly CM, Callery JC, Hapiro J, et al. The pivotal role of 5-lipoxygenase products in the reaction of aspirin-sensitive asthmatics to aspirin. Am Rev Respir Dis 1993;148:1447-51.
83. 83. Pauls JD, Simon RA, Daffern P, Stevenson DD. Effectiveness of the 5-LO inhibitor zileuton during oral challenges in aspirin-sensitive asthmatics. J Allergy Clin Immunol 1999;103:S229.
84. 84. Dahlen B, Nizankowska E, Szczeklik A, Zetterström O, Bochenek G, Kumlin M, et al. Benefits from adding the 5-lipoxygenase inhibitor zileuton to conventional therapy in aspirin-intolerant asthmatics. Am J Respir Crit Care Med 1998;157:1187-94.
85. 85. Kuna P, Malmstrom K, Dahlen S-E, Nizankowska E, Kowalski M, Stevenson D, et al. Montelukast (MK-0476) a CysLT1 receptor antagonist improves asthma control in aspirin-intolerant asthmatic patients [abstract]. Am J Respir Crit Care Med 1997;155:A975.
86. 86. Wechsler ME, Garpestad E, Flier SR, Kocher O, Weiland DA, Polito AJ, et al. Pulmonary infiltrates, eosinophilia and cardiomyopathy following corticosteroid withdrawal in patients with asthma receiving zafirlukast. JAMA 1998;279:455-7.
87. 87. Churg A, Churg J. Steroids and the Churg-Strauss syndrome. Lancet 1998;352:32.
88. 88. Green RL, Vayonis AG. Churg-Strauss syndrome after zafirlukast in two patients not receiving systemic steroid treatment. Lancet 1999;353:725-6.
89. 89. Szczeklik A, Mastalerz L, Nizankowska E, Cmiel A. Protective and bronchodilator effects of prostaglandin E and salbutamol in aspirin-induced asthma. Am J Respir Crit Care Med 1996;153:567-71.
90. 90. Mastalerz L, Milewski M, Duplaga M, Nizankowska E, Szczeklik A. Intranasal fluticasone propionate for chronic eosinophilic rhinitis in patients with aspirin-induced asthma. Allergy 1997;52:895-900.